Myelodysplastic syndrome
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Myelodysplastic syndrome
- Therapeutic area
- Hematology
- myelodysplastic syndrome
- MDS
- MDS, unclassifiable
- MDS-U
- Myelodysplastic Syndromes
- dysmyelopoietic syndrome
- hematopoeitic - myelodysplastic syndrome (MDS)
- myelodysplasia
- myelodysplastic neoplasm
- myelodysplastic syndrome
- myelodysplastic syndrome, somatic
- myelodysplastic syndrome, unclassifiable
- myelodysplastic syndrome/neoplasm
- myelodysplastic syndromes
- oligoblastic leukaemia
- oligoblastic leukemia
- preleukemia
- smoldering leukemia
- smouldering leukaemia
- Disease mechanisms
- Syndromic
- Severity
- Severe
- Hematology
- Oncology
- MONDO ID
- MONDO:0018881
- Parent condition
- MONDO:0015756
Related records
Broader conditions (12)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Myeloid hemopathy
- Neoplasm
- Neoplastic disease or syndrome
- Neoplastic syndrome
- Syndromic disease
Narrower conditions (15)
- Aregenerative anemia
- Childhood myelodysplastic syndrome
- Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome
- Familial monosomy 7 syndrome
- Monosomy 7 myelodysplasia and leukemia syndrome 1
- Monosomy 7 myelodysplasia and leukemia syndrome 2
- Myelodysplastic syndrome associated with isolated del(5q)
- Myelodysplastic syndrome with excess blasts
- Myelodysplastic syndrome with excess blasts-1
- Myelodysplastic syndrome with excess blasts-2
- Myelodysplastic syndrome with multilineage dysplasia
- Myelodysplastic syndrome with ring sideroblasts
- Myelodysplastic syndrome with single lineage dysplasia
- Refractory anemia with excess blasts in transformation
- Refractory cytopenia of childhood
Trials (2,254)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
- 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)
- 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome
- 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
- 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS
- 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
- A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Approved drugs (8)
- Azacitidine
- Cedazuridine
- Decitabine
- Deferasirox
- Epoetin alfa
- Lenalidomide
- Lenalidomide hydrochloride monohydrate
- Luspatercept
Drugs in development (288)
- A27.15 Phase 1
- Acetaminophen Phase 2
- Aclarubicin Phase 1
- Adakitug Phase 1
- Adavosertib Phase 1
- AHN-12 Phase 1
- Aldesleukin Phase 3
- Alemtuzumab Phase 3
- Alisertib Phase 2
- Allopurinol Phase 2
- Alrizomadlin Phase 1
- Amifostine Phase 2
- Ammonium trichlorotellurate Phase 2
- Amphotericin B Phase 3
- Amsacrine Phase 3
- AMV-564 Phase 1
- Ancestim Early phase 1
- Anidulafungin Phase 2
- Antilymphocyte immunoglobulin (horse) Phase 2
- APVO-436 Phase 1
Other linked drugs (5)
- Dasatinib
- Imetelstat sodium
- Omidubicel
- Pelabresib
- Tamnorzatinib